Press release
Gene Therapy in Ophthalmology Market Set to Surge at 14.8% CAGR, Reaching USD 6.5 Billion by 2034
Gene Therapy in Ophthalmology Market
Gene therapy is revolutionizing ophthalmology by offering the potential to treat and even cure previously untreatable genetic eye diseases. By targeting the underlying genetic defects responsible for conditions such as retinitis pigmentosa, Leber congenital amaurosis (LCA), X-linked retinitis pigmentosa (XLRP), and Stargardt disease, gene therapy is reshaping the future of vision care.
Unlike traditional therapies that only manage symptoms, gene therapies aim to restore or preserve vision by repairing defective genes or introducing functional copies. The approval of the first ophthalmology gene therapy, Luxturna (voretigene neparvovec, Spark Therapeutics/Roche), marked a historic milestone. Since then, numerous therapies have entered clinical trials, expanding the pipeline across rare and common ocular diseases.
With increasing investments, regulatory support for orphan drugs, and technological innovation in delivery systems, the gene therapy in ophthalmology market is poised for robust growth through 2034.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72308
Market Overview
• Market Size (2024): USD 1.6 billion
• Forecast (2034): USD 6.5 billion
• CAGR (2024-2034): ~14.8%
Key Highlights:
• Growing prevalence of inherited retinal diseases (IRDs) and unmet medical needs.
• Expanding clinical trial pipeline targeting both rare and more prevalent ocular diseases.
• Regulatory incentives for orphan drugs accelerating market entry.
• Advances in vector design, CRISPR technology, and ocular drug delivery systems enhancing outcomes.
Leading Players: Roche/Spark Therapeutics, Novartis, REGENXBIO, Biogen, MeiraGTx, AGTC (Applied Genetic Technologies Corporation), Editas Medicine, BlueRock Therapeutics, and emerging biotech innovators.
Key Drivers: Rising prevalence of genetic eye diseases, technological breakthroughs, and increasing patient advocacy.
Key Challenges: High treatment costs, manufacturing complexity, and long-term safety concerns.
Segmentation Analysis
By Product
• Approved Gene Therapies (Luxturna and others in pipeline)
• Viral Vector-Based Therapies (AAV, lentivirus)
• Non-Viral Gene Therapies (nanoparticles, liposomes)
• CRISPR-Based Gene Editing Platforms
• Adjunctive Tools (diagnostic genetic testing, delivery systems)
By Platform
• In Vivo Gene Therapy Platforms
• Ex Vivo Platforms (for experimental ophthalmic applications)
• AI-Integrated Screening & Genomics Platforms
By Technology
• Adeno-Associated Virus (AAV) Vectors
• Lentiviral & Retroviral Vectors
• CRISPR-Cas9 and Next-Gen Gene Editing Tools
• RNA-Based Therapies (antisense oligonucleotides, mRNA therapies)
• Sustained Delivery Systems for Ocular Applications
By End Use
• Hospitals & Specialty Eye Centers
• Ophthalmology Clinics
• Research Institutes & Academic Centers
• Biotechnology & Pharma R&D Units
By Application
• Inherited Retinal Diseases (LCA, RP, XLRP, Stargardt disease)
• Age-Related Macular Degeneration (wet and dry forms)
• Diabetic Retinopathy & Diabetic Macular Edema
• Glaucoma (experimental gene targets)
• Clinical Research & Trials
Summary: While IRDs remain the primary focus, the market is expanding into common ocular diseases like AMD and diabetic retinopathy, which will dramatically increase patient access and market size.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72308/gene-therapy-in-ophthalmology-market
Regional Analysis
North America
• Largest market, with the U.S. leading in FDA approvals, clinical trials, and R&D investment.
• Strong presence of biotech innovators and established pharma.
• Robust reimbursement frameworks for orphan drugs.
Europe
• Germany, UK, and France at the forefront of gene therapy research.
• EMA approvals and regulatory incentives accelerating market growth.
• Expanding patient registries for inherited retinal diseases.
Asia-Pacific
• Fastest-growing region, driven by expanding clinical trial activity in Japan, China, and South Korea.
• Rising patient populations and investments in genomics research.
• Increasing government funding for rare disease treatment access.
Middle East & Africa
• GCC nations investing in advanced ophthalmic care and rare disease therapies.
• Limited access in African nations, but partnerships with global organizations improving awareness.
• Growing role of medical tourism for advanced gene therapies.
Latin America
• Brazil and Mexico emerging as key regional markets.
• Gradual introduction of genetic testing and early trial participation.
• Rising demand for advanced ophthalmology treatments in private healthcare.
Summary: North America and Europe currently dominate due to approvals and innovation, while Asia-Pacific is the fastest-growing region, fueled by demographic shifts, research investments, and government support for rare disease programs.
Market Dynamics
Growth Drivers
1. Unmet Needs: Lack of curative treatments for inherited retinal diseases.
2. Technological Advancements: CRISPR and next-gen vectors improving efficacy and safety.
3. Regulatory Incentives: Orphan drug designations accelerating approvals.
4. Patient Advocacy: Strong global movements raising awareness and funding.
Challenges
1. High Costs: Single-treatment gene therapies priced in the hundreds of thousands of dollars.
2. Manufacturing Complexity: Scaling up viral vector production remains difficult.
3. Long-Term Safety: Durability of treatment outcomes under continued evaluation.
4. Access Inequalities: Limited affordability in developing economies.
Latest Trends
• CRISPR Integration: Expanding applications in inherited retinal disorders.
• Dual & Triple Vector Systems: Expanding gene delivery for large genes.
• AI in Genomics: Supporting patient selection and trial optimization.
• Partnerships & M&A: Big pharma acquiring biotech startups to expand pipelines.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72308
Competitor Analysis
Major Players:
• Roche/Spark Therapeutics (Luxturna)
• Novartis AG
• REGENXBIO Inc.
• Biogen Inc.
• MeiraGTx Holdings Plc
• AGTC (Applied Genetic Technologies Corporation)
• Editas Medicine
• BlueRock Therapeutics
• Nightstar Therapeutics (acquired by Biogen)
• Emerging CRISPR-focused startups in ophthalmology
Competitive Dynamics:
The gene therapy in ophthalmology market is innovation-driven, with early-mover companies like Roche/Spark and Novartis leading. Intense competition exists among biotech startups advancing AAV-based and CRISPR therapies, while large pharma companies pursue strategic acquisitions and partnerships. The pipeline is rapidly diversifying beyond IRDs to target AMD and diabetic retinopathy, which will transform the competitive landscape.
Conclusion
The gene therapy in ophthalmology market is projected to grow from USD 1.6 billion in 2024 to USD 6.5 billion by 2034, at a CAGR of ~14.8%. Growth is driven by expanding clinical trials, regulatory incentives, and breakthroughs in vector technology and gene editing.
While high costs, safety concerns, and manufacturing challenges remain, the long-term outlook is transformative. Over the next decade, gene therapy is expected to expand from rare inherited retinal diseases to more common conditions like AMD and diabetic retinopathy, vastly increasing market potential.
This report is also available in the following languages : Japanese (眼科市場における遺伝子治療), Korean (안과 시장의 유전자 치료), Chinese (眼科基因治疗市场), French (Thérapie génique sur le marché de l'ophtalmologie), German (Gentherapie im Markt für Augenheilkunde), and Italian (Terapia genica nel mercato dell'oftalmologia), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72308
Our More Reports:
Optic Neuritis Market
https://exactitudeconsultancy.com/reports/72238/optic-neuritis-market
Neurotrophic Keratitis Market
https://exactitudeconsultancy.com/reports/72236/neurotrophic-keratitis-market
Myopic Macular Degeneration (MMD) Market
https://exactitudeconsultancy.com/reports/72234/myopic-macular-degeneration-mmd-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gene Therapy in Ophthalmology Market Set to Surge at 14.8% CAGR, Reaching USD 6.5 Billion by 2034 here
News-ID: 4194222 • Views: …
More Releases from Exactitude Consultancy
Panuveitis Market to Reach USD 2.9 Billion by 2034
Panuveitis is a severe form of uveitis in which all layers of the uvea (iris, ciliary body, and choroid) are inflamed. It often results in blurred vision, eye pain, redness, light sensitivity, and floaters. The condition can be triggered by autoimmune diseases, infections, or idiopathic causes, and if untreated, can cause irreversible vision loss, glaucoma, cataracts, and retinal complications.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72271
The increasing prevalence…
Tonometers Market Projected to Grow at 7.3% CAGR, Reaching USD 730 Million by 20 …
Introduction
Tonometers are essential ophthalmic diagnostic devices used to measure intraocular pressure (IOP), a key risk factor for glaucoma. Early detection of elevated IOP is critical, as glaucoma is one of the leading causes of irreversible blindness worldwide. Regular screening through tonometry allows ophthalmologists to diagnose and manage the disease before significant vision loss occurs.
The tonometers market is evolving with the introduction of non-contact (air-puff) devices, handheld portable solutions, digital…
Ophthalmoscopes Market Poised to Grow at 7.2% CAGR, Reaching USD 640 Million by …
Introduction
Ophthalmoscopes are essential diagnostic instruments used by ophthalmologists and optometrists to examine the interior of the eye, particularly the retina, optic nerve, and blood vessels. These devices play a critical role in detecting and monitoring conditions such as glaucoma, diabetic retinopathy, macular degeneration, hypertension-related changes, and other retinal disorders.
The global demand for ophthalmoscopes is expanding due to the rising prevalence of eye diseases, aging populations, and growing emphasis on early…
Persistent Epithelial Defect (PEDs) Market to Reach USD 2.5 Billion by 2034
Persistent epithelial defects (PEDs) are corneal lesions where the corneal epithelium fails to heal within two weeks despite standard therapy. They arise from multiple causes, including ocular trauma, corneal infections, neurotrophic keratitis, dry eye disease, post-surgical complications, and autoimmune conditions. PEDs can lead to scarring, secondary infections, corneal perforation, and vision loss, making effective management essential.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72273
The global market is driven by…
More Releases for Gene
DNA and Gene Cloning Services Market Expands with Growing Focus on Complex Gene …
InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global DNA and Gene Cloning Services Market by Type of Service Offered (Custom Cloning, Sub-cloning, Gene Synthesis, and Others), Type of Gene (Complex Gene, Standard Gene, and Others), End-User Industry (Pharmaceutical, Academic and R&D, and Biotechnology Companies, and Others)- Market Outlook and Industry Analysis 2034"
The DNA and Gene Cloning Services Market Size is valued…
Evolving Market Trends In The CRISPR Gene Editing Industry: Innovative Gene Ther …
The CRISPR Gene Editing Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected CRISPR Gene Editing Market Size During the Forecast Period?
The CRISPR gene editing market has grown exponentially in recent years. It will grow from $2.26 billion in 2024 to $2.88…
Cell and Gene Therapy Market Global Analysis By Type (Cell Therapy, Gene Therapy …
Gene and cell therapy uses genes and cells for the treatment of genetic diseases. Genetic diseases are caused by mutations, or errors in genes which can be passed down from one generation to another. Gene therapy aims to treat diseases by using genetic material, or DNA, to manipulate a patient's cells by replacing, changing or introducing genome into cells- either internally or externally. Cell therapy aims to treat diseases by…
Competitive and Opportunities Analysis of Gene Therapy Market of Gene Therapy Ma …
Global Gene Therapy Market accounted for US$ 2.05 billion in 2020 and is estimated to be US$ 12.29 billion by 2030 and is anticipated to register a CAGR of 19.8%. Gene therapy means fixing a working gene to an individual who features a damaged gene. The European Commission has approved this method for one particular treatment. The treatment by the merchandise Glybera uses an epidemic to infect muscle cells with…
Genetic Testing Market Size by Growth Opportunities, Top Key Players: GeneDx, In …
Genetic Testing Market Report provides an in-depth analysis of the overall market, The ripple effect of Coronavirus-Covid19 on the market needs to become part of strategy discussions to emerge strong. The report focuses on major key players, production details, their application, countries and also analyzes the global and key regions market potential and advantage, opportunity, and challenge, restraints, and risks.
The Top players Covered in report are GeneDx, Invitae, Pathway Genomics,…
Gene Synthesis Market by Top Manufacturers - Gene script, Gene Art (Thermofische …
The "Gene Synthesis Market" report Added by "Big Market Research", enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.
In the Gene Synthesis Market 2018 research report professionals describe the different facets of the industry with a specific goal…
